Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Phase 1/2 Unknown 26 enrolled David Minor, MD California Pacific Medical Center · collab Jefferson Medical College of Thomas Jefferson University · collab University of Chicago · collab

NaSingle-groupOpen-labelTreatment

Summary

Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.

Timeline

Start: 2016-10-10
Primary completion: 2022-01
Completion: 2023-06

Publications

Minor DR, Kim KB, Tong RT, Wu MC, Kashani-Sabet M, Orloff M, Eschelman DJ, Gonsalves CF, Adamo RD, Anne PR, Luke JJ, Char D, Sato T. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Cancer Biother Radiopharm. 2022 Feb;37(1):11-16. doi: 10.1089/cbr.2021.0366. Epub 2022 Jan 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	1 mg/kg	—
Subject	Nivolumab	Monoclonal antibody	480 mg	—

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Summary

Timeline

Publications

Drugs

Indications